| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | CD27 |
| Clinical data | |
| Other names | CDX-1127 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6486H9992N1740O2022S42 |
| Molar mass | 146043.96 g·mol−1 |
Varlilumab (INN;[1] development codeCDX-1127) is amonoclonal antibody designed forimmunotherapy for solid tumors and hematologic malignancies.[2] It is an anti-CD27 antibody and helpsactivate T-cells.[3]
This drug was developed by Celldex Therapeutics.
It (in combination withONT-10) has undergone a phase 1B clinical trial for advanced breast or ovarian cancer.[4] In combination with anti-PD-1nivolumab it has undergone a phase 1/2 trial for advanced refractory solid tumours[5]
 | Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it. |
